

For brokers and producers only

Date: October 17, 2019

Market: **All (Except Medicare Supplement)**

New Quantity Limits on Proton Pump Inhibitors (PPIs)

Proton pump inhibitors are a group of drugs used to reduce stomach acid production. The FDA-approved indications for these medications specify duration of treatment. For several conditions, short-term treatment of 4-8 weeks is usually sufficient, however many patients remain on long-term therapy unnecessarily.

On October 1, CareFirst extended the existing quantity limits for PPIs on the Exchange Formulary to Commercial Formularies 1, 2 and 3. This change applies to all PPIs and includes an initial limit of 90 units per 365 days, regardless of strength. The initial 90 units of therapy allows time for the provider to evaluate the patient's diagnosis and establish a treatment plan. Members who require longer therapy may continue treatment if they meet prior authorization criteria.

Notifications were sent to prescribers as well as the approximately 30,000 [impacted members](#).

For more information

If you have any questions, please contact your broker sales representative.